Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 4/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 12/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.36 |
| ▸ | SHBG | P04278 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SNCA | P37840 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945370 | 0.91 | STS (0.40) | STSHRH3SIGMAR1HSD17B1ESR1 | |
| SCHEMBL15804294 | 0.91 | STS (0.40) | STSHRH3SIGMAR1HSD17B1ESR1 | |
| SCHEMBL1659489 | 0.91 | STS (0.40) | STSHRH3SIGMAR1HSD17B1ESR1 | |
| SCHEMBL1659869 | 0.90 | STS (0.40) | STSHRH3SIGMAR1HSD17B1ESR1 | |
| SCHEMBL1657382 | 0.85 | ESR1 (0.53) | STSHSD17B1ESR1ESR2HSD17B10 | |
| SCHEMBL12225839 | 0.85 | SIGMAR1 (0.37) | STSHRH3SIGMAR1HSD17B1ESR1 | |
| SCHEMBL12225837 | 0.85 | HRH3 (0.50) | HRH3SIGMAR1HSD17B1ESR1ESR2 | |
| SCHEMBL12225841 | 0.84 | HRH3 (0.49) | HRH3SIGMAR1HSD17B1ESR1ESR2 | |
| SCHEMBL14396390 | 0.83 | ESR1 (0.42) | STSHSD17B1ESR1ESR2HSD17B10 | |
| SCHEMBL12225838 | 0.83 | ESR1 (0.36) | STSHRH3HSD17B1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847548-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | Sri International (US) | 2007-10-24 | — | — | EP | claimed |
| US-6548491-B2 | For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated | SRI INTERNATIONAL | 2003-04-15 | — | — | US | claimed |
| EP-2305694-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | SRI International (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1847548-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | Sri International (US) | 2007-10-24 | — | — | EP | disclosed |
| US-6747018-B2 | TREATMENT OF ESTROGEN-DEPENDENT DISORDERS; PREFERRED COMPOUNDS HAVE 1,3,5-ESTRATRIENE NUCLEUS, AND ARE SUBSTITUTED AT C-17 OR C-11 WITH MOLECULAR MOIETY WHICH RENDERS COMPOUNDS EFFECTIVE TO BLOCK BINDING OF ESTROGEN TO ITS RECEPTOR | SRI INTERNATIONAL | 2004-06-08 | — | — | US | disclosed |
| US-20030153543-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2003-08-14 | — | — | US | disclosed |
| EP-1310509-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | Sri International (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6548491-B2 | For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated | SRI INTERNATIONAL | 2003-04-15 | — | — | US | disclosed |
| US-6503896-B1 | 17-Desoxy-1,3,5-estratriene derivatives; postmenopause, osteoporosis, central nervous system disorders; anticarcinogenic and hypotensive agents | SRI INTERNATIONAL | 2003-01-07 | — | — | US | disclosed |
| US-6455517-B1 | FOR THERAPY OF CONDITIONS OR DISEASES THAT ARE ESTROGEN-DEPENDENT, I.E., ARE ESTROGEN-INDUCED OR ESTROGEN-STIMULATED | SRI INTERNATIONAL | 2002-09-24 | — | — | US | disclosed |
| US-20020032180-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2002-03-14 | — | — | US | disclosed |
| US-20020032181-A1 | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2002-03-14 | — | — | US | disclosed |
| US-6281205-B1 | 1,3,5(10)-ESTRATRIENE NUCLEUS, SUBSTITUTED AT THE C-17 POSITION WITH AN AMINE AND ETHER-CONTAINING GROUP | SRI INTERNATIONAL | 2001-08-28 | — | — | US | disclosed |
| US-6054446-A | 17-SUBSTITUTED-17-DESOXY-1,3,5-ESTRATRIENES. | SRI INTERNATIONAL (US) | 2000-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032181-A1 | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | STS 597/4885HRH3 2058/4885SIGMAR1 353/4885 |
| US-20030153543-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | STS 559/4885HRH3 2248/4885SIGMAR1 400/4885 |
| US-20020032180-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | STS 559/4885HRH3 2248/4885SIGMAR1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.